| Schedule (route) | Endpoint | Vehicle | Dose | Treated/Control (%) | Observations |
|---|---|---|---|---|---|
| Q03HX008 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q03HX008 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q03HX008 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 161.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q03HX008 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 176.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q03HX016 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 98.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q03HX016 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q03HX016 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 160.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q03HX016 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 196.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q03HX024 (ip) | median survival time | saline with Tween-80 | 0.4 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q03HX024 (ip) | median survival time | saline with Tween-80 | 0.6 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q03HX024 (ip) | median survival time | saline with Tween-80 | 0.9 mg/kg/injection | 232.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q03HX024 (ip) | median survival time | saline with Tween-80 | 1.3 mg/kg/injection | 209.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q03HX024 (ip) | median survival time | saline with Tween-80 | 2.0 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q03HX024 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q03HX024 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q03HX024 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 206.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q03HX024 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 87.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 2.0 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 26; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 2.0 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 2.0 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 8; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 2.5 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 2.5 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 3.0 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 7; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 3.0 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 68; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 4.0 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 26; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 4.0 mg/kg/injection | 163.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 4.0 mg/kg/injection | 141.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 4.0 mg/kg/injection | 154.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 4.0 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 4.0 mg/kg/injection | 156.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 4.0 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 4.0 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 8; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 5.0 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 7; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 5.0 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 5.0 mg/kg/injection | 185.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 5.0 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 68; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 5.3 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 5.3 mg/kg/injection | 141.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 5.3 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 5.3 mg/kg/injection | 154.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 6.0 mg/kg/injection | 179.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 6.0 mg/kg/injection | 182.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 6.0 mg/kg/injection | 177.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 6.0 mg/kg/injection | 161.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 6.0 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 45; 04/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 6.0 mg/kg/injection | 175.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 8.0 mg/kg/injection | 158.0 | Antitumor endpoint evaluated on day 26; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 8.0 mg/kg/injection | 156.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 8.0 mg/kg/injection | 201.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 8.0 mg/kg/injection | 190.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 8.0 mg/kg/injection | 182.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 8.0 mg/kg/injection | 182.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 8.0 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 8.0 mg/kg/injection | 166.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 8.0 mg/kg/injection | 182.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 8.0 mg/kg/injection | 186.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 8.0 mg/kg/injection | 174.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 8.0 mg/kg/injection | 184.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 8.0 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 8; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 8.4 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 7; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 8.4 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 68; 07/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 10.0 mg/kg/injection | 184.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 10.0 mg/kg/injection | 211.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 10.0 mg/kg/injection | 161.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 10.0 mg/kg/injection | 182.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 10.0 mg/kg/injection | 95.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 10.0 mg/kg/injection | 207.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 10.0 mg/kg/injection | 135.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 10.0 mg/kg/injection | 182.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 10.0 mg/kg/injection | 170.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 12.0 mg/kg/injection | 96.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 12.0 mg/kg/injection | 392.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 12.0 mg/kg/injection | 186.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline | 14.0 mg/kg/injection | 163.0 | Antitumor endpoint evaluated on day 7; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 14.0 mg/kg/injection | 75.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 14.0 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 68; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 16.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 26; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 16.0 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 8; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 16.0 mg/kg/injection | 74.0 | Antitumor endpoint evaluated on day 5; 06/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 18.0 mg/kg/injection | 71.0 | Antitumor endpoint evaluated on day 5; 04/07 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 20.0 mg/kg/injection | 90.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 20.0 mg/kg/injection | 73.0 | Antitumor endpoint evaluated on day 5; 08/09 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 5; 04/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 40.0 mg/kg/injection | 70.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline | 40.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 5; 08/01 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 3.5 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 4.0 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 5.3 mg/kg/injection | 135.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 5.3 mg/kg/injection | 133.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 5.3 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 5.3 mg/kg/injection | 160.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 5.3 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 5.3 mg/kg/injection | 154.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 5.3 mg/kg/injection | 160.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 6.0 mg/kg/injection | 156.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 8.0 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 8.0 mg/kg/injection | 167.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 8.0 mg/kg/injection | 169.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 8.0 mg/kg/injection | 181.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 8.0 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 8.0 mg/kg/injection | 149.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 8.0 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 8.0 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 10.0 mg/kg/injection | 95.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 10.0 mg/kg/injection | 158.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 10.0 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 12.0 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 12.0 mg/kg/injection | 201.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 12.0 mg/kg/injection | 198.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 12.0 mg/kg/injection | 183.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 12.0 mg/kg/injection | 87.0 | Antitumor endpoint evaluated on day 5; 04/07 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 15.0 mg/kg/injection | 187.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 15.0 mg/kg/injection | 197.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 15.0 mg/kg/injection | 179.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | median survival time | saline with Tween-80 | 15.0 mg/kg/injection | 167.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 97.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 149.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 149.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 6.0 mg/kg/injection | 166.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | mean survival time | saline | 8.0 mg/kg/injection | 160.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 8.0 mg/kg/injection | 161.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | mean survival time | saline | 8.0 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 8.0 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 8.0 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 154.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 191.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 186.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX001 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 187.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 162.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 289.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 16.0 mg/kg/injection | 180.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 16.0 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 97.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 275.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 267.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 97.0 | Antitumor endpoint evaluated on day 60; 08/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 06/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 32.0 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 40.0 mg/kg/injection | 93.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 40.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 04/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 40.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 04/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline | 40.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 00/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | Klucel (hydroxypropylcellulose) (HPC) | 0.6 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | Klucel (hydroxypropylcellulose) (HPC) | 1.25 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | Klucel (hydroxypropylcellulose) (HPC) | 2.5 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | Klucel (hydroxypropylcellulose) (HPC) | 5.0 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | Klucel (hydroxypropylcellulose) (HPC) | 10.0 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | Klucel (hydroxypropylcellulose) (HPC) | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | Klucel (hydroxypropylcellulose) (HPC) | 40.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline with Tween-80 | 5.3 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline with Tween-80 | 5.3 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline with Tween-80 | 5.3 mg/kg/injection | 150.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline with Tween-80 | 5.3 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | mean survival time | saline with Tween-80 | 5.3 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | mean survival time | saline with Tween-80 | 5.3 mg/kg/injection | 158.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | mean survival time | saline with Tween-80 | 5.3 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline with Tween-80 | 8.0 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline with Tween-80 | 8.0 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline with Tween-80 | 8.0 mg/kg/injection | 169.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | mean survival time | saline with Tween-80 | 8.0 mg/kg/injection | 159.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | mean survival time | saline with Tween-80 | 8.0 mg/kg/injection | 158.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX001 (ip) | mean survival time | saline with Tween-80 | 8.0 mg/kg/injection | 187.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline with Tween-80 | 8.0 mg/kg/injection | 157.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline with Tween-80 | 12.0 mg/kg/injection | 300.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline with Tween-80 | 12.0 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on day 5 |
| Q01DX001 (ip) | mean survival time | saline with Tween-80 | 12.0 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on day 5 |
| Q01DX001 (ip) | mean survival time | saline with Tween-80 | 12.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 60; 08/10 animals surviving on day 5 |
| Q01DX001 (ip) | mean survival time | saline with Tween-80 | 12.0 mg/kg/injection | 191.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline with Tween-80 | 12.0 mg/kg/injection | 226.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline with Tween-80 | 12.0 mg/kg/injection | 170.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline with Tween-80 | 15.0 mg/kg/injection | 163.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline with Tween-80 | 15.0 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 60; 09/09 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline with Tween-80 | 15.0 mg/kg/injection | 244.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | saline with Tween-80 | 15.0 mg/kg/injection | 179.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | water | 0.5 mg/kg/injection | 96.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | water | 0.5 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | water | 0.5 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | water | 1.0 mg/kg/injection | 92.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | water | 1.0 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | water | 1.0 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | water | 2.0 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | water | 2.0 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | water | 2.0 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | water | 2.0 mg/kg/injection | 92.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | water | 4.0 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | water | 4.0 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | water | 4.0 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | water | 4.0 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | water | 8.0 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | water | 8.0 mg/kg/injection | 94.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | water | 8.0 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | water | 8.0 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | water | 16.0 mg/kg/injection | 87.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | water | 16.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | water | 32.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | water | 32.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | other | 0.6 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | other | 1.25 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | other | 2.5 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | other | 5.0 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | other | 10.0 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | other | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | other | 40.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | dextrose | 0.5 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | dextrose | 0.5 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | dextrose | 1.0 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | dextrose | 1.0 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | dextrose | 1.0 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | dextrose | 1.0 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | dextrose | 2.0 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | dextrose | 2.0 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | dextrose | 2.0 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | dextrose | 2.0 mg/kg/injection | 93.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | dextrose | 4.0 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | dextrose | 4.0 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | dextrose | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 01/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | dextrose | 4.0 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | dextrose | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 01/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | dextrose | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | dextrose | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 01/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | dextrose | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | dextrose | 16.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | dextrose | 16.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | dextrose | 16.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (ip) | mean survival time | dextrose | 16.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (iv) | median survival time | saline | 1.94 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 6; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (iv) | median survival time | saline | 3.24 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 6; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (iv) | median survival time | saline | 5.4 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 6; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (iv) | median survival time | saline | 9.0 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 6; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (iv) | median survival time | saline | 15.0 mg/kg/injection | 163.0 | Antitumor endpoint evaluated on day 6; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (oral) | mean survival time | saline | 5.0 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (oral) | mean survival time | saline | 10.0 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (oral) | mean survival time | saline | 20.0 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (oral) | mean survival time | saline | 40.0 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (oral) | mean survival time | saline | 80.0 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 60; 07/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX001 (oral) | mean survival time | saline | 160.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 04/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | median survival time | saline | 2.5 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 5.0 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 10.0 mg/kg/injection | 269.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q01DX005 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 184.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | saline | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | saline with Tween-80 | 1.8 mg/kg/injection | 156.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | saline with Tween-80 | 1.8 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX005 (ip) | mean survival time | saline with Tween-80 | 2.7 mg/kg/injection | 181.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | saline with Tween-80 | 2.7 mg/kg/injection | 160.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | saline with Tween-80 | 2.7 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | saline with Tween-80 | 2.7 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | saline with Tween-80 | 2.7 mg/kg/injection | 189.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | saline with Tween-80 | 2.7 mg/kg/injection | 158.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX005 (ip) | mean survival time | saline with Tween-80 | 3.0 mg/kg/injection | 170.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | saline with Tween-80 | 4.0 mg/kg/injection | 217.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | saline with Tween-80 | 4.0 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | saline with Tween-80 | 4.0 mg/kg/injection | 165.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX005 (ip) | mean survival time | saline with Tween-80 | 4.0 mg/kg/injection | 200.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | saline with Tween-80 | 4.0 mg/kg/injection | 168.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | saline with Tween-80 | 4.0 mg/kg/injection | 195.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | saline with Tween-80 | 5.0 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | saline with Tween-80 | 6.0 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | saline with Tween-80 | 6.0 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | saline with Tween-80 | 6.0 mg/kg/injection | 87.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | saline with Tween-80 | 6.0 mg/kg/injection | 98.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | water | 0.5 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | water | 1.0 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | water | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (ip) | mean survival time | water | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (oral) | mean survival time | saline with Tween-80 | 3.12 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (oral) | mean survival time | saline with Tween-80 | 6.25 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (oral) | mean survival time | saline with Tween-80 | 12.5 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (oral) | mean survival time | sodium bicarbonate | 1.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (oral) | mean survival time | sodium bicarbonate | 2.0 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (oral) | mean survival time | sodium bicarbonate | 4.0 mg/kg/injection | 96.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (oral) | mean survival time | sodium bicarbonate | 8.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (oral) | mean survival time | sodium bicarbonate | 16.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX005 (oral) | mean survival time | sodium bicarbonate | 32.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 01/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX007 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX007 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 195.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX007 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.2 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.25 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.4 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.4 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.4 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 133.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.5 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 5; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 0.8 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.8 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 0.8 mg/kg/injection | 204.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 133.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 156.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 5; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.0 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.25 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.6 mg/kg/injection | 192.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.6 mg/kg/injection | 218.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 1.6 mg/kg/injection | 182.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 193.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 177.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 198.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 167.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 177.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 168.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 162.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 191.0 | Antitumor endpoint evaluated on day 5; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 174.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.0 mg/kg/injection | 212.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.4 mg/kg/injection | 176.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.4 mg/kg/injection | 232.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.4 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 05/05 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 2.5 mg/kg/injection | 159.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 158.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 87.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 91.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 168.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 135.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 161.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 146.0 | Antitumor endpoint evaluated on day 5; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 98.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 4.0 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 5.0 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 0.58 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 0.87 mg/kg/injection | 135.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 0.87 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 1.0 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 1.3 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 1.3 mg/kg/injection | 158.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 2.0 mg/kg/injection | 165.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 2.0 mg/kg/injection | 141.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 2.0 mg/kg/injection | 156.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 4.0 mg/kg/injection | 201.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 0.13 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.13 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.13 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.13 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.13 mg/kg/injection | 99.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 98.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 35; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.32 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 08/08 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 0.32 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.32 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.32 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.32 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.32 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.4 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 35; 02/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 08/08 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 08/08 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 0.8 mg/kg/injection | 141.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 159.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 135.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 35; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 146.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 158.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 150.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 135.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 157.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 150.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 150.0 | Antitumor endpoint evaluated on day 60; 08/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 135.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 08/08 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 178.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 30; 08/08 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 1.6 mg/kg/injection | 203.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 168.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 176.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 164.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 195.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 194.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 158.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 173.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 96.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 157.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 203.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 168.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 185.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 166.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 182.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 177.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 173.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 165.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 202.0 | Antitumor endpoint evaluated on day 35; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 191.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 158.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 173.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 171.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 176.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 162.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 133.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 188.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.4 mg/kg/injection | 170.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 190.0 | Antitumor endpoint evaluated on day 30; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 207.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 187.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 195.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 192.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 164.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 180.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 187.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 187.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 188.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 184.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 183.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 164.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 174.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 176.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 179.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 189.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 193.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 174.0 | Antitumor endpoint evaluated on day 30; 08/08 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 189.0 | Antitumor endpoint evaluated on day 30; 08/08 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 174.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 202.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 180.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 97.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 157.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 89.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 95.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 94.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 96.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 97.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 96.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 91.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 96.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 97.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 97.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 89.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 08/08 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 30; 08/08 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 88.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 07/08 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/08 animals surviving on day 5 |
| Q01DX009 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 06/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 00/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 06/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 04/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 08/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 08/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 08/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 08/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 03/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 16.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline | 16.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | Klucel (hydroxypropylcellulose) (HPC) | 0.25 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | Klucel (hydroxypropylcellulose) (HPC) | 0.5 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | Klucel (hydroxypropylcellulose) (HPC) | 1.0 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | Klucel (hydroxypropylcellulose) (HPC) | 2.0 mg/kg/injection | 177.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | Klucel (hydroxypropylcellulose) (HPC) | 4.0 mg/kg/injection | 93.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | Klucel (hydroxypropylcellulose) (HPC) | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 01/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline with Tween-80 | 0.25 mg/kg/injection | 97.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline with Tween-80 | 0.5 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline with Tween-80 | 1.0 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | saline with Tween-80 | 2.0 mg/kg/injection | 170.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.12 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.12 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.25 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.25 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.25 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.25 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.25 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.25 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.25 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.25 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.25 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.25 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.25 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.25 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.5 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.5 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.5 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.5 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.5 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.5 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.5 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.5 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.5 mg/kg/injection | 133.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.5 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.5 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.5 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.5 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.5 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.5 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.5 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.5 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.5 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.63 mg/kg/injection | 150.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.63 mg/kg/injection | 133.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.63 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.63 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.63 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.63 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.63 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.63 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.63 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.63 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.63 mg/kg/injection | 156.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.63 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.63 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.63 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.63 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 0.63 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.0 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.0 mg/kg/injection | 88.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.0 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.0 mg/kg/injection | 87.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.0 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.0 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.0 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.0 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.0 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.0 mg/kg/injection | 92.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.0 mg/kg/injection | 92.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.0 mg/kg/injection | 97.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.25 mg/kg/injection | 149.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.25 mg/kg/injection | 167.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.25 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.25 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.25 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.25 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.25 mg/kg/injection | 146.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.25 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.25 mg/kg/injection | 98.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.25 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.25 mg/kg/injection | 163.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.25 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.25 mg/kg/injection | 156.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.25 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.25 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 1.25 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.0 mg/kg/injection | 88.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.0 mg/kg/injection | 88.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.5 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.5 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.5 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 02/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.5 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 05/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.5 mg/kg/injection | 93.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.5 mg/kg/injection | 89.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.5 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 06/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.5 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.5 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.5 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.5 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.5 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.5 mg/kg/injection | 97.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.5 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 04/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.5 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 06/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 2.5 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 08/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 04/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 04/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 01/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 01/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 08/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 04/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 00/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 00/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 05/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 00/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 02/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 00/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 00/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 01/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 00/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 00/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 00/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 00/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 00/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 00/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 00/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 00/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 01/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 00/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 00/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 01/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | other | 0.25 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | other | 0.5 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | other | 0.5 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | other | 1.0 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | other | 1.0 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | other | 2.0 mg/kg/injection | 160.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | other | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | other | 4.0 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | other | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | other | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | other | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 01/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | other | 16.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | suspension in saline | 0.5 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | suspension in saline | 1.0 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | suspension in saline | 2.0 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | suspension in saline | 4.0 mg/kg/injection | 98.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | suspension in saline | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | suspension in saline | 16.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | dextrose | 0.25 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | dextrose | 0.5 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | dextrose | 0.5 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | dextrose | 1.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | dextrose | 1.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | dextrose | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | dextrose | 2.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | dextrose | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | dextrose | 4.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 01/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | dextrose | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (ip) | mean survival time | dextrose | 16.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (oral) | mean survival time | saline | 1.25 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (oral) | mean survival time | saline | 2.5 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (oral) | mean survival time | saline | 5.0 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (oral) | mean survival time | saline | 10.0 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (oral) | mean survival time | saline | 20.0 mg/kg/injection | 96.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (oral) | mean survival time | saline | 40.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 08/10 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (oral) | mean survival time | sodium bicarbonate | 1.0 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (oral) | mean survival time | sodium bicarbonate | 2.0 mg/kg/injection | 96.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (oral) | mean survival time | sodium bicarbonate | 4.0 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (oral) | mean survival time | sodium bicarbonate | 8.0 mg/kg/injection | 93.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (oral) | mean survival time | sodium bicarbonate | 16.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/06 animals surviving on tox evaluation day (usually day 5) |
| Q01DX009 (oral) | mean survival time | sodium bicarbonate | 32.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q02DX005 (ip) | median survival time | saline | 1.5 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 6; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q02DX005 (ip) | median survival time | saline | 3.0 mg/kg/injection | 181.0 | Antitumor endpoint evaluated on day 6; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q02DX005 (ip) | median survival time | saline | 6.0 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 6; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q02DX005 (ip) | median survival time | saline | 12.0 mg/kg/injection | 98.0 | Antitumor endpoint evaluated on day 6; 08/08 animals surviving on tox evaluation day (usually day 5) |
| Q03DX003 (ip) | median survival time | saline | 2.0 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q03DX003 (ip) | median survival time | saline | 2.0 mg/kg/injection | 171.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q03DX003 (ip) | median survival time | saline | 4.0 mg/kg/injection | 159.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q03DX003 (ip) | median survival time | saline | 4.0 mg/kg/injection | 195.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q03DX003 (ip) | median survival time | saline | 6.0 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q03DX003 (ip) | median survival time | saline | 6.0 mg/kg/injection | 179.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q03DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 45; 05/05 animals surviving on day 5 |
| Q03DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q03DX003 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q03DX003 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q03DX003 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 168.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX002 (ip) | mean survival time | saline with Tween-80 | 100.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 01/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX002 (ip) | mean survival time | saline with Tween-80 | 200.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX002 (ip) | mean survival time | saline with Tween-80 | 400.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX002 (oral) | median survival time | saline | 20.0 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX002 (oral) | median survival time | saline | 30.0 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX002 (oral) | median survival time | saline | 40.0 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX002 (oral) | median survival time | saline | 50.0 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 0.5 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.0 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.0 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 170.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 40; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 20; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 20; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 133.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 20; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 98.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 206.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 177.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 60; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 1.25 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.0 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.0 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 5; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.0 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.0 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 5; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 135.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 168.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 146.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 154.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 141.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 174.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 154.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 180.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 180.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 170.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 182.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 177.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 146.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 150.0 | Antitumor endpoint evaluated on day 40; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 156.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 160.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 20; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 158.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 160.0 | Antitumor endpoint evaluated on day 20; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 164.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 186.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 182.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 164.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 162.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 162.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 180.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 171.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 171.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 173.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 168.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 20; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 177.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 150.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 135.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 135.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 141.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 161.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 154.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 141.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 60; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 16; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 156.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 89.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 211.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.5 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 2.9 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 6; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 189.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 180.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 3.5 mg/kg/injection | 174.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 4.0 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 30; 09/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 4.0 mg/kg/injection | 183.0 | Antitumor endpoint evaluated on day 5; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 4.0 mg/kg/injection | 163.0 | Antitumor endpoint evaluated on day 5; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 4.0 mg/kg/injection | 207.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 4.8 mg/kg/injection | 183.0 | Antitumor endpoint evaluated on day 6; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 180.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 197.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 163.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 180.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 231.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 168.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 157.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 190.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 225.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 257.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 178.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 178.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 160.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 213.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 175.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 201.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 195.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 159.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 216.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 162.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 175.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 191.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 188.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 190.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 197.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 194.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 352.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 352.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 246.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 160.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 86.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 209.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 213.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 188.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 240.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 209.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 183.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 216.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 222.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 229.0 | Antitumor endpoint evaluated on day 40; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 296.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 240.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 235.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 212.0 | Antitumor endpoint evaluated on day 20; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 212.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 219.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 222.0 | Antitumor endpoint evaluated on day 20; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 361.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 361.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 344.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 189.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 235.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 250.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 219.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 219.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 212.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 212.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 205.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 205.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 215.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 215.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 352.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 337.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 337.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 208.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 179.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 222.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 200.0 | Antitumor endpoint evaluated on day 20; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 166.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 232.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 193.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 193.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 87.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 235.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 253.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 225.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 209.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 209.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 195.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 200.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 164.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 164.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 150.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 158.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 174.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 146.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 170.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 141.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 170.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 146.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 268.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 160.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 201.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 150.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 240.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 195.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 200.0 | Antitumor endpoint evaluated on day 60; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 175.0 | Antitumor endpoint evaluated on day 16; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 192.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 175.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 159.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 186.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 192.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 178.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 201.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 174.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 209.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 197.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 244.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.0 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 189.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 277.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 236.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 210.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 168.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 200.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 5.3 mg/kg/injection | 200.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 6.0 mg/kg/injection | 214.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 193.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 166.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 316.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 280.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 261.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 317.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 204.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 232.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 165.0 | Antitumor endpoint evaluated on day 5; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 6; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 8.0 mg/kg/injection | 232.0 | Antitumor endpoint evaluated on day 5; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 161.0 | Antitumor endpoint evaluated on day 20; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 348.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 243.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 253.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 186.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 186.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 236.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 236.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 280.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 280.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 294.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 294.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 352.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 337.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 337.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 181.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 181.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 160.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 214.0 | Antitumor endpoint evaluated on day 20; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 250.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 162.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 226.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 195.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 164.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 161.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 161.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 150.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 162.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 183.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 176.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 175.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 176.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 241.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 191.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 170.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 159.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 175.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 188.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 250.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 175.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 197.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 218.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 159.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 182.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 280.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 201.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 96.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 175.0 | Antitumor endpoint evaluated on day 60; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 175.0 | Antitumor endpoint evaluated on day 16; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 166.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 192.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 190.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 348.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 302.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 239.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 352.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 352.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 167.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 176.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 209.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 282.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 185.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 301.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 308.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 256.0 | Antitumor endpoint evaluated on day 40; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 184.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 277.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 20; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 256.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 233.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 211.0 | Antitumor endpoint evaluated on day 30; 09/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 209.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 179.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 302.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 190.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 349.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 298.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 222.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 224.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 238.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 159.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 290.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 158.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 256.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 212.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 98.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 188.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 174.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 169.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 246.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 10.0 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 12.0 mg/kg/injection | 93.0 | Antitumor endpoint evaluated on day 5; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 12.0 mg/kg/injection | 159.0 | Antitumor endpoint evaluated on day 5; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 13.3 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 6; 02/02 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 160.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 222.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 98.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 348.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 191.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 154.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 162.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 92.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 231.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 95.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 01/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 95.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 96.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 89.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 89.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 20; 03/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 96.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 01/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 88.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 88.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 146.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 08/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 01/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 08/08 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 16; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 200.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 160.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 93.0 | Antitumor endpoint evaluated on day 30; 05/05 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 96.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 93.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 96.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 40; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 20; 00/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 20; 04/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 1.25 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 1.25 mg/kg/injection | 96.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 2.5 mg/kg/injection | 141.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 2.5 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 3.5 mg/kg/injection | 163.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 5.0 mg/kg/injection | 235.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 5.0 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 5.3 mg/kg/injection | 243.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 8.0 mg/kg/injection | 231.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 10.0 mg/kg/injection | 247.0 | Antitumor endpoint evaluated on day 45; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 10.0 mg/kg/injection | 175.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 10.0 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline with Tween-80 | 20.0 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline + alcohol | 1.25 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline + alcohol | 2.5 mg/kg/injection | 156.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline + alcohol | 5.0 mg/kg/injection | 211.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline + alcohol | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | median survival time | saline + alcohol | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 95.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 35; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 98.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 0.63 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 20; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 98.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 141.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 60; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 35; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 05/05 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 04/04 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 04/04 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 149.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.25 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 1.5 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 20; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.38 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 146.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 04/04 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 04/04 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 135.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 88.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 154.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 168.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 141.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 60; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 173.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 161.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 146.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 156.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 135.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 135.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 141.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 150.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 135.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 154.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 146.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 156.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 146.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 35; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 161.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 157.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 05/05 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 165.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 133.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.5 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 2.9 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 3.0 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 3.0 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 3.0 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 3.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 3.0 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 3.56 mg/kg/injection | 150.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 170.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 158.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 219.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 149.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 162.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 20; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 150.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 4.4 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 4.4 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 4.4 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 4.4 mg/kg/injection | 150.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 4.8 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 164.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 182.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 200.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 168.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 261.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 213.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 158.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 157.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 162.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 235.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 204.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 197.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 189.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 174.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 184.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 239.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 236.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 169.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 189.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 179.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 163.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 180.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 197.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 185.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 203.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 186.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 228.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 217.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 201.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 225.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 157.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 182.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 163.0 | Antitumor endpoint evaluated on day 60; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 203.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 170.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 164.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 186.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 146.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 161.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 178.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 166.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 87.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 166.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 169.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 187.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 168.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 240.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 146.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 168.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 159.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 181.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 161.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 166.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 158.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 175.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 161.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 175.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 159.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 160.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 182.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 160.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 166.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 166.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 167.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 156.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 159.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 157.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 150.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 135.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 150.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 180.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 159.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 170.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 161.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 201.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 180.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 141.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 173.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 175.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 168.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 150.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 201.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 163.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 170.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 167.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 166.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 152.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 167.0 | Antitumor endpoint evaluated on day 30; 05/05 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 162.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 190.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 162.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 174.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 186.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 149.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 165.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 164.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 178.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 164.0 | Antitumor endpoint evaluated on day 35; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 171.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 175.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 176.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 178.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 181.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 164.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 185.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 04/04 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 04/04 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 146.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 156.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 178.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 183.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 154.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 162.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 193.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 150.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 164.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.0 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 5.34 mg/kg/injection | 163.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 6.0 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 6.0 mg/kg/injection | 226.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 6.6 mg/kg/injection | 187.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 6.6 mg/kg/injection | 190.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 6.6 mg/kg/injection | 209.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 6.6 mg/kg/injection | 160.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 8.0 mg/kg/injection | 191.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 8.0 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 8.0 mg/kg/injection | 161.0 | Antitumor endpoint evaluated on day 20; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 8.0 mg/kg/injection | 197.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 8.0 mg/kg/injection | 189.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 8.0 mg/kg/injection | 198.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 8.0 mg/kg/injection | 86.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 8.0 mg/kg/injection | 176.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 8.0 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 45; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 8.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 146.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 98.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 181.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 167.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 176.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 157.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 164.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 198.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 86.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 206.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 179.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 91.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 170.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 149.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 90.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 01/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 159.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 174.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 228.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 176.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 95.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 166.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 166.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 195.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 213.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 160.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 221.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 135.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 226.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 231.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 212.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 88.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 135.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 203.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 159.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 165.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 175.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 185.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 168.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 269.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 145.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 97.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 165.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 146.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 90.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 60; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 156.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 220.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 171.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 155.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 96.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 92.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 35; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 183.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 161.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 96.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 97.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 87.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 157.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 170.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 141.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 205.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 95.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 175.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 90.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 97.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 95.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 90.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 200.0 | Antitumor endpoint evaluated on day 35; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 244.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 171.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 90.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 88.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 05/05 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 01/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 96.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 04/04 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 95.0 | Antitumor endpoint evaluated on day 30; 04/04 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 90.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 10.0 mg/kg/injection | 147.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 12.0 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 12.0 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 13.3 mg/kg/injection | 78.0 | Antitumor endpoint evaluated on day 5; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 15.0 mg/kg/injection | 87.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 15.0 mg/kg/injection | 91.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 15.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 15.0 mg/kg/injection | 87.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 16.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 16.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 16.0 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 20; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 18.0 mg/kg/injection | 86.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 35; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 01/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 88.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 96.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 98.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 90.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 86.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 88.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 86.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 86.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 93.0 | Antitumor endpoint evaluated on day 35; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 94.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 149.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 86.0 | Antitumor endpoint evaluated on day 30; 02/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 90.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 86.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 06/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 03/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 07/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 06/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 02/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 07/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 08/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 04/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 06/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 07/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 06/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 87.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 07/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 91.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 01/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 93.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 88.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 89.0 | Antitumor endpoint evaluated on day 60; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 91.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 01/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 95.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 86.0 | Antitumor endpoint evaluated on day 30; 04/05 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 01/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/04 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/04 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | Klucel (hydroxypropylcellulose) (HPC) | 0.6 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | Klucel (hydroxypropylcellulose) (HPC) | 1.25 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | Klucel (hydroxypropylcellulose) (HPC) | 1.25 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | Klucel (hydroxypropylcellulose) (HPC) | 2.5 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | Klucel (hydroxypropylcellulose) (HPC) | 2.5 mg/kg/injection | 133.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | Klucel (hydroxypropylcellulose) (HPC) | 5.0 mg/kg/injection | 187.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | Klucel (hydroxypropylcellulose) (HPC) | 5.0 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | Klucel (hydroxypropylcellulose) (HPC) | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | Klucel (hydroxypropylcellulose) (HPC) | 10.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | Klucel (hydroxypropylcellulose) (HPC) | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 01/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | Klucel (hydroxypropylcellulose) (HPC) | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 0.78 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 0.78 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 1.25 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 1.25 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 1.56 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 1.56 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 1.56 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 1.56 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 1.56 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 2.5 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 2.5 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 3.12 mg/kg/injection | 168.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 3.12 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 3.12 mg/kg/injection | 193.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 3.12 mg/kg/injection | 170.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 3.12 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 3.12 mg/kg/injection | 156.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 3.12 mg/kg/injection | 154.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 3.5 mg/kg/injection | 144.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 3.5 mg/kg/injection | 150.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 3.5 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 3.5 mg/kg/injection | 163.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 3.5 mg/kg/injection | 163.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 5.0 mg/kg/injection | 197.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 5.0 mg/kg/injection | 89.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 5.3 mg/kg/injection | 168.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 5.3 mg/kg/injection | 198.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 5.3 mg/kg/injection | 201.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 5.3 mg/kg/injection | 189.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 5.3 mg/kg/injection | 188.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 6.25 mg/kg/injection | 180.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 6.25 mg/kg/injection | 176.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 6.25 mg/kg/injection | 188.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 6.25 mg/kg/injection | 209.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 6.25 mg/kg/injection | 212.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 6.25 mg/kg/injection | 191.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 6.25 mg/kg/injection | 186.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 8.0 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 8.0 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 8.0 mg/kg/injection | 176.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 8.0 mg/kg/injection | 200.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 8.0 mg/kg/injection | 210.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 12.5 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 12.5 mg/kg/injection | 89.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | saline with Tween-80 | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q04DX003 (ip) | mean survival time | water | 0.63 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.0 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.0 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.0 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.0 mg/kg/injection | 108.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.0 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.0 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.25 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.25 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.25 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.25 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 04/04 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.25 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.25 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.25 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.25 mg/kg/injection | 150.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.25 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.25 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.25 mg/kg/injection | 142.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.25 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.25 mg/kg/injection | 137.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.25 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.25 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.25 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.25 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.25 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.25 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.25 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.25 mg/kg/injection | 149.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.25 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.25 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 1.25 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.0 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.0 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.0 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.0 mg/kg/injection | 141.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.0 mg/kg/injection | 146.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.0 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.5 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.5 mg/kg/injection | 117.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.5 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.5 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.5 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.5 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.5 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.5 mg/kg/injection | 132.0 | Antitumor endpoint evaluated on day 30; 04/04 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.5 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.5 mg/kg/injection | 98.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.5 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.5 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.5 mg/kg/injection | 138.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.5 mg/kg/injection | 119.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.5 mg/kg/injection | 143.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.5 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.5 mg/kg/injection | 131.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.5 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.5 mg/kg/injection | 146.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.5 mg/kg/injection | 134.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.5 mg/kg/injection | 141.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.5 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.5 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 2.5 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 4.0 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 4.0 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 4.0 mg/kg/injection | 97.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 4.0 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 4.0 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 4.0 mg/kg/injection | 146.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 5.0 mg/kg/injection | 88.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 5.0 mg/kg/injection | 96.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 5.0 mg/kg/injection | 93.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 5.0 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 5.0 mg/kg/injection | 88.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 5.0 mg/kg/injection | 90.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 5.0 mg/kg/injection | 107.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 5.0 mg/kg/injection | 109.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 5.0 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 5.0 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 04/04 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 5.0 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 5.0 mg/kg/injection | 95.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 5.0 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 5.0 mg/kg/injection | 129.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 8.0 mg/kg/injection | 92.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 8.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 8.0 mg/kg/injection | 90.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 10.0 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/04 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 10.0 mg/kg/injection | 103.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 16.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 16.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 16.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 16.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 16.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 01/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 20.0 mg/kg/injection | 89.0 | Antitumor endpoint evaluated on day 30; 04/04 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 03/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 01/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 01/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 01/03 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | water | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | other | 0.6 mg/kg/injection | 97.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | other | 1.25 mg/kg/injection | 115.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | other | 2.5 mg/kg/injection | 126.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | other | 5.0 mg/kg/injection | 191.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | other | 10.0 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | other | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 02/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | suspension in saline | 1.0 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | suspension in saline | 2.0 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | suspension in saline | 4.0 mg/kg/injection | 150.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | suspension in saline | 8.0 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 1.25 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 1.25 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 1.25 mg/kg/injection | 118.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 1.25 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 1.25 mg/kg/injection | 153.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 1.25 mg/kg/injection | 124.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 1.25 mg/kg/injection | 140.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 2.5 mg/kg/injection | 154.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 2.5 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 2.5 mg/kg/injection | 93.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 2.5 mg/kg/injection | 136.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 2.5 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 2.5 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 2.5 mg/kg/injection | 86.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 5.0 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 5.0 mg/kg/injection | 89.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 5.0 mg/kg/injection | 114.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 5.0 mg/kg/injection | 172.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 5.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 01/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 01/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 01/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (ip) | mean survival time | dextrose | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 00/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (sc) | mean survival time | acid diluted with saline | 1.25 mg/kg/injection | 106.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (sc) | mean survival time | acid diluted with saline | 2.5 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (sc) | mean survival time | acid diluted with saline | 5.0 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (sc) | mean survival time | acid diluted with saline | 10.0 mg/kg/injection | 94.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (sc) | mean survival time | acid diluted with saline | 20.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (oral) | mean survival time | saline | 2.5 mg/kg/injection | 102.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (oral) | mean survival time | saline | 5.0 mg/kg/injection | 112.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (oral) | mean survival time | saline | 10.0 mg/kg/injection | 123.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (oral) | mean survival time | saline | 20.0 mg/kg/injection | 130.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (oral) | mean survival time | saline | 40.0 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q04DX003 (oral) | mean survival time | saline | 80.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 08/10 animals surviving on tox evaluation day (usually day 5) |
| Q08DX002 (ip) | mean survival time | saline | 2.0 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q08DX002 (ip) | mean survival time | saline | 4.0 mg/kg/injection | 146.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q08DX002 (ip) | mean survival time | saline | 8.0 mg/kg/injection | 197.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q08DX002 (ip) | mean survival time | saline | 16.0 mg/kg/injection | 127.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on tox evaluation day (usually day 5) |
| Q#A X018 (ip) | mean survival time | saline | 0.13 mg/kg/injection | 116.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q#A X018 (ip) | mean survival time | saline | 0.25 mg/kg/injection | 120.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q#A X018 (ip) | mean survival time | saline | 0.5 mg/kg/injection | 128.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |
| Q#A X018 (ip) | mean survival time | saline | 1.0 mg/kg/injection | 148.0 | Antitumor endpoint evaluated on day 30; 03/03 animals surviving on tox evaluation day (usually day 5) |